Driving rapid cell line selection using integrated analytical workflows

Cell line creation is a major success factor in biologics manufacturing. It establishes the basis for product yield, quality, and long-term process stability. However, despite significant breakthroughs in host engineering, vector systems, and culture conditions, early-stage clone selection is still one of the least analytically supported stages of development.¹

Therapeutic proteins, including monoclonal antibodies, enzymes, and fusion proteins, are becoming increasingly essential components of current treatments for cancer, autoimmune diseases, and genetic disorders.

Each of these modalities requires a well-characterized and scalable manufacturing cell line. This makes cell line development a technical requirement and strategic imperative for biopharmaceutical companies.

Download the full whitepaper to learn more

References

1. Tejwani, V., et al. (2021). High‐throughput and automation advances for accelerating single‐cell cloning, monoclonality and early phase clone screening steps in mammalian cell line development for biologics production. Biotechnology Progress. DOI: 10.1002/btpr.3208. https://aiche.onlinelibrary.wiley.com/doi/abs/10.1002/btpr.3208.

About Abselion

Abselion started in 2018, at that time under the name HexagonFab, in a small corner of a laboratory at the University of Cambridge.

We set out with the humble goal to make protein research simpler. Scientists should be able to pursue their passion for discovery and innovation, rather than spend their valuable time with tedious, manual tasks. With RED we had access to the ideal technology to create this product. A product that is so compact that it could fit on every bench, and so affordable that it is accessible to everyone. Over the years we have designed, built and tested our first product Amperia and we’re proud to introduce it to the world.​

Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.